Tumor CD45+ cells and spleen LY6G+ PMNs isolated from Hdc-GFP mice with subcutaneous ACKP syngeneic GC line-established tumors and treated with TFF2-MSA and/or anti-PD-1 therapies.

ABSTRACT: We designed a novel TFF2-MSA peptide as a CXCR4 partial agonist, and used it either alone or in combination with anti-PD-1 to treat established ACKP tumors. PMNs are known to be highly heterogenous, thus these tumors are grown in Hdc-GFP host mice to trace Hdc+ PMN subsets. We then used single cell-RNA sequencing (scRNA-seq) to elucidate the effect of TFF2-MSA on tumor and spleen PMNs, and more broadly the tumor microenvironment.

ORGANISM(S): Mus musculus

PROVIDER: GSE279330 | GEO | 2025/05/23

REPOSITORIES: GEO